Institutional investors purchased a net $1.2 million shares of ENTA during the quarter ended June 2015. This may signal that the smart money is gaining interest in this company as the 81.76% of shares outstanding that institutional investors hold is actually below the Biotechnology industry average.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
BLACKROCK FUND ADVISORS Bought 534.7 Thousand shares of Enanta Pharmaceuticals In...